Menu

The temporary second skin

Shift to Synthetics

SUPRATHEL® is a proven synthetic skin substitute that has revolutionized the treatment of epidermal and dermal wounds. Since its launch more than 20 years ago, it has significantly influenced the switch to synthetic products and is now used in more than 40 countries worldwide as a standard treatment for second-degree burn wounds and split thickness skin graft (STSG) donor sites.

Like a second skin

Like a second skin, SUPRATHEL® gently covers the wound and promotes rapid, complication-free healing. Developed analogously to the human skin, SUPRATHEL® has the same important properties such as elasticity, water vapour permeability and impermeability to bacteria.

Single application

SUPRATHEL® is applied only once to the previously cleaned, debrided, and disinfected wound and remains there until complete healing. After application, the membrane becomes transparent and allows the healing process to be evaluated.

Contact us →

Scald

Patient: Male, 5 years
Etiology: Scald injury, left hand
Degree: Mixed burn wounds of degree 2a, small parts 2b

View case →

Multiple removal of split skin

Patient: Male, 13 years
Etiology: The only available donor site was on the upper part of the scalp
Degree: Mixed burn wounds, 95% TBSA

View case →

Large-scale burn wounds

Patient: Male, 38 years
Etiology: Large-scale burn wounds, upper body
Degree: 95% TBSA, ABSI 13, mainly degree 2a/2b, partial 3

View case →

Wounds caused by TEN

Patient: Female, 48 years
Etiology: TEN (Toxic Epidermal Necrolysis, Lyell’s Syndrome)
Degree: Skin lesions degree 2a, 80% TBSA

View case →

Electric burns on hands

Patient: Male, 59 years
Etiology: Electric burns, hands
Degree: Mainly degree 2a/2b, partial 3

View case →

Indications

SUPRATHEL® is intended for the treatment of wounds that include:

  • Epidermal and dermal wounds
  • Split-thickness skin graft (STSG) donor sites
  • Second-degree burn areas (2a/2b)
  • Second-degree burns mixed with 3rd degree burned areas

SUPRATHEL® is available in many configurations to enable a customised treatment for different types of wounds in each patient.

Benefits

Single application, no change of SUPRATHEL® necessary

Significant pain relief 1-4 – up to 60%

  • Less anesthesia and pain medication required1,5-6

Low rate of infections1,2,5,7-9, no biologic risk

  • Synthetic, biocompatible, absorbable
  • No reported allergic reactions

Fast wound healing1,2,5

  • Improved epithelialization3-11

Lower treatment costs2,4,5

  • Less cost and effort for dressing changes2,9
  • Shorter hospital stay5

Excellent cosmetic outcomes and scar quality4,7,8

Low inflammatory reaction12

Reduced transplantation rate6

Composition

SUPRATHEL® is a purely synthetic product and therefore does not bear any of the potential residual risks that can occur with biological products of human or animal origin. Depending on the application, products based on SUPRA EPT™ technology can be degraded by the body down to the elementary compounds CO2 and H2O – a gentle and completely biocompatible process.

Polymer:
Lacto-capromer

Degradation:
Hydrolytic (to CO2 and H2O)

Permeability to water vapor:
40 – 70 ml/m2 per hour, 1,000 – 1,700 ml/m2 per day

Porosity:
70% – 80%

Supporting materials

Contact your local representative for additional materials.

Read more →

“SUPRATHEL® represents an integral armamentarium in burn
surgery.”

Lect. MD. Lars-Peter Kamolz, M. Sc, Vienna

1 Schwarze et al. Burns. 2007 Nov;33(7):850-4 | 2 Schwarze et al. Ann Plast Surg. 2008 Feb;60(2):181-5 | 3 Uhlig et al. Burns. 2007 Mar;33(2):221-9 | 4 Kaartinen et al. J Plast Surg Hand Surg. 2011 Sep;45(4-5):200-3 | 5 Everett et al. J Wound Care. 2015 Jul;24(7):S4-8 | 6 Schriek et al. Eur Burn J. 2022 Dec;3(1):1–9 | 7 Keck et al. Burns. 2012 May;38(3):388-95 | 8 Hundeshagen et al. J Burn Care Res. 2018 Feb 20;39(2):261-7 | 9 Markl et al. Ann Plast Surg. 2010 Nov;65(5):490-6 | 10 Gurunluoglu et al. J Burn Care Res. 2019 Jun 21;40(4):444-50 | 11 Gurunluoglu et al. J Burn Care Res. 2019 Apr 26;40(3):302-11 | 12 Demircan et al. Ulus Travma Acil Cerrahi Derg. 2021 Jan;27(1):122-31